In partnership with
From the desk of Dr. Kevin, MD
“Everybody please put the champagne back in the refrigerator.”
Your Cancer Just Got Its Own Wanted Poster
A few days ago, something pretty wild happened in cancer medicine.
Moderna and Merck announced that their Phase 3 trial of an individualized mRNA treatment for melanoma succeeded. The combination improved both recurrence-free survival and distant metastasis-free survival compared with Keytruda alone.
Wall Street responded calmly and professionally.
Moderna’s stock went up 177% in one day.
Apparently investors heard “personalized cancer treatment” and began throwing money at their screens like grandparents discovering QVC.
But forget the stocks. The actual science is much more interesting.
Also, sorry if I’m sounding nerdy today…
First, this isn't your normal vaccine
The treatment is called intismeran autogene, previously known as mRNA-4157/V940.
And calling it a “cancer vaccine” can be confusing.
You don't receive it to prevent yourself from catching melanoma at Costco.
This is a therapeutic, individualized treatment created after someone already has cancer.
The Phase 3 trial included 1,137 people with high-risk stage IIB-IV melanoma whose tumors had been completely surgically removed. Patients received Keytruda alone or Keytruda plus the individualized mRNA therapy.
The goal you ask?
Kill microscopic cancer cells that might still be hanging around after surgery like tenants who have technically been evicted but somehow still have a key.
Here's where it gets ridiculous
Cancer cells accumulate mutations.
Those mutations can create abnormal proteins called neoantigens, essentially molecular fingerprints that distinguish tumor cells from healthy cells.
Doctors sequence DNA from the patient's tumor and compare it with healthy DNA.
An algorithm then selects up to 34 tumor-specific neoantigens and Moderna manufactures an mRNA treatment specifically for that patient.
Read that again.
Patient A and Patient B can have the same diagnosis and receive different mRNA medicines.
We have officially entered the portion of medicine where your medication needs to be custom-made because apparently cancer wasn't already high-maintenance enough.
Once injected, the mRNA provides instructions that help expose these tumor-specific targets to the immune system, encouraging T cells to recognize them.
Meanwhile, Keytruda performs a different job.
Keytruda removes the handbrake
Tumors are sneaky little bastards.
They can exploit the PD-1/PD-L1 pathway, which normally helps prevent excessive immune activity.
Keytruda blocks PD-1.
So imagine your T cells are security guards.
The individualized mRNA therapy slides them photographs saying:
“These 34 gentlemen are banned from the premises.”
Keytruda then removes the manager who keeps telling security:
"Guys, maybe don't make a fucking scene here?"
Now the immune system can recognize tumor targets and attack more effectively.
That combination is the clever part.
So… did we cure melanoma?
Everybody please put the champagne back in the refrigerator.
The Phase 3 announcement is extremely encouraging, but Moderna and Merck haven't released the detailed numbers yet. (cof-cof…typical)
What we currently know is that the study achieved statistically significant and clinically meaningful improvements in recurrence-free survival and distant metastasis-free survival. Overall survival data are still immature.
There is, however, another reason scientists are excited.
An earlier randomized Phase 2b trial has now followed patients for about five years. Adding intismeran to Keytruda reduced the relative risk of recurrence or death by 49% and distant metastasis or death by 59% compared with Keytruda alone.
And researchers are already studying this strategy in other cancers.
The practical takeaway
For now, nothing changes about preventing melanoma.
Use sunscreen. Avoid tanning beds. Watch changing moles. Get suspicious lesions examined.
But medically, this could represent something much bigger:
Instead of simply asking,
“What cancer does this patient have?”
we may increasingly ask,
“What exact mutations does this patient's cancer have?”
Then manufacture a treatment accordingly.
Cancer spent decades becoming personalized.
Medicine finally took that personally.
Until next Saturday,
Kevin Cutthebull, MD
What did you think of This Week's Edition?
AI Is Moving Fast. Here's How to Keep Up.
AI is moving faster than any other technology. New models. New tools. New claims. New noise.
Most people feel like they're behind. But the people that don't, aren't smarter. They're just better informed.
The Future Today is a daily briefing for people who want clarity. In one concise email each day, you'll get the most important AI and tech developments, learn why they matter, and what they signal about what's coming next.
Written for operators, builders, leaders, and anyone who wants to sound sharp when AI comes up in the meeting.
One email. Five Minutes. Stay ahead of 99% of the world.
